Related references
Note: Only part of the references are listed.Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials
Edith A. Perez et al.
MAYO CLINIC PROCEEDINGS (2012)
A novel ErbB2 epitope targeted by human antitumor immunoagents
Fulvia Troise et al.
FEBS JOURNAL (2011)
The Vulnerability of the Heart As a Pluricellular Paracrine Organ Lessons From Unexpected Triggers of Heart Failure in Targeted ErbB2 Anticancer Therapy
Gilles W. De Keulenaer et al.
CIRCULATION RESEARCH (2010)
Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury
Kevin Bersell et al.
CELL (2009)
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents
Gennaro Riccio et al.
FASEB JOURNAL (2009)
ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium
Stephen J. Fuller et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2008)
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin
C. De Lorenzo et al.
BRITISH JOURNAL OF CANCER (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Neuregulin activates erbB2-dependent Src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes
Yukio Kuramochi et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2006)
Biological properties of a human compact anti-ErbB2 antibody
C De Lorenzo et al.
CARCINOGENESIS (2005)
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
HA Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
DB Agus et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
ErbB2 is essential in the prevention of dilated cardiomyopathy
SA Crone et al.
NATURE MEDICINE (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
